AGP Executive Report
Last update: 10 hours agoDEA Rescheduling Hearing: The U.S. DEA will kick off a major Monday hearing on moving marijuana from Schedule I to Schedule III, with supporters arguing it better matches medical practice and opponents warning it could fuel more commercial growth. Doctor Access Pressure: New Zealand medical researchers warn doctors could face legal risk and patient backlash as regulators push faster cannabis-based medicine access without enough trial, safety, and efficacy data. Sleep & Dependence Debate: A National Sleep Foundation-funded survey finds nearly 10% of U.S. adults use cannabis to sleep, but users report poorer sleep quality and the research can’t tell if cannabis causes the problem or people use it because sleep is already bad. Local Retail Vote: Vermont’s Royalton considers putting retail cannabis to a voter ballot, after neighboring towns opted in under Act 164. Cannabis in the Wild: A report on DR Congo’s FDLR alleges the militia’s funding includes a cannabis trade, with MONUSCO personnel described as major customers. Wisconsin Legalization Push: A fresh opinion piece argues Wisconsin’s prohibition stance is out of step with public support and neighboring states’ tax revenue. CBD Mental Health Claim: A reader letter asks whether CBD could help with serious adolescent mental health care, citing schizophrenia-related claims.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
